Home
http://www.virbac.fr/ http://www.boehringer-ingelheim.com/ http://www.novartis.com/ http://www.animalhealth.bayerhealthcare.com/
vetcontact
Vetrinär
Tiermedizin
  WELCOME  
vetcontact
Vetrinär
Tiermedizin
  Privacy Policy  
  Home  
  Login / Newsletter  
vetcontact
Vetrinär
Tiermedizin
  CONTACTS  
vetcontact
Vetrinär
Tiermedizin
  Classifieds  
  New Products  
  VetCompanies  
  VetSchools  
vetcontact
Vetrinär
Tiermedizin
  PROFESSION  
vetcontact
Vetrinär
Tiermedizin
  Edutainment  
  VetAgenda  
  Presentations  
  Posters  
  ESAVS  
  Specialisation  
vetcontact
Vetrinär
Tiermedizin
  INSIGHT  
vetcontact
Vetrinär
Tiermedizin
  Congress News  
  Picture Galleries  
vetcontact
Vetrinär
Tiermedizin
  PRODUCTS  
vetcontact
Vetrinär
Tiermedizin
  Bayer  
  Boehringer Ing.  
  Novartis  
  Virbac

 
  Simply book for less...  
    

Bovine    Equine    Small Animal Practice    Swine Practice    Articles    Vetjournal    
deutsch english español polski francais
Home / WELCOME / Archiv / Small Animal Practice /     
 
VAC Protocol for Dogs with Stage III Hemangiosarcoma
Hemangiosarcomas (HSAs) are aggressive tumors with a high rate of metastasis. Clinical stage has been considered a negative prognostic factor for survival. The study authors hypothesized that the median survival time (MST) of dogs with metastatic (stage III) HSA treated with a vincristine, doxorubicin, and cyclophosphamide (VAC) chemotherapy protocol would not be different than those with stage I/II HSA. Is this correct?

Sixty-seven dogs with HSA in different anatomic locations were evaluated retrospectively.

All dogs received the VAC protocol as an adjuvant to surgery (n = 50), neoadjuvant (n = 3), or as the sole treatment modality (n = 14).

There was no significant difference (P = 0.97) between the MST of dogs with stage III and stage I/II HSA.

For dogs presenting with splenic HSA alone, there was no significant difference between the MST of dogs with stage III and stage I/II disease (P = 0.12).

The overall response rate (complete response [CR] and partial response [PR]) was 86%).

No unacceptable toxicities were observed.

Dogs with stage III HSA treated with the VAC protocol have a similar prognosis to dogs with stage I/II HSA.

Dogs with HSA and evidence of metastases at the time of diagnosis should not be denied treatment.



Source: Francisco J. Alvarez, Kenji Hosoya, Ana Lara-Garcia, William Kisseberth, Guillermo Couto (2013): VAC Protocol for Treatment of Dogs with Stage III Hemangiosarcoma
In: Published online before print September 19, 2013, doi: 10.5326/JAAHA-MS-5954 Journal of the American Animal Hospital Association Nov/Dec 2013 jaaha.5954






Tell a friend   |   Print version   |   Send this article

SMALL ANIMAL PRACTICE

Proteasome inhibitors for canine and human osteosarcomamembers
Osteosarcoma, a common malignancy in large dog breeds, typically metastasises from long bones to lungs and is usually fatal within 1 to 2 years of diagnosis. Better therapies are needed for canine patients and their human counterparts, a third of whom die within 5 years of diagnosis. The authors compared the in vitro sensitivity of canine osteosarcoma cells derived from 4 tumours to the currently used chemotherapy drugs doxorubicin and carboplatin, and 4 new anti‐cancer drugs.

  • Pharmacokinetics of a novel mirtazapine transdermal ointment in catsmembers
  • Bacterial contamination in 50% dextrose vials after multiple puncturesmembers
  • Sotalol and the ventricular systolic function in dogs with ventricular arrhythmiasmembers
  • Life-threatening arterial haemorrhage during nephrectomymembers
  • Update to the chinchilla retinamembers
  • Vocal fold granulomas in brachycephalic dogsmembers
  • Extracellular vesicles in mammary cancer of dogs and catsmembers
  • Immunocytochemical assay using aqueous humor to diagnose feline infectious peritonitis members
  • Microbiota of traumatic, open fracture wounds and the mechanism of injury members
  • False-positive CT and radiography results for bronchial collapse in healthy dogsmembers
  • Variability of SDMA in apparently healthy dogsmembers
  • Bioavailability of suppository acetaminophen in dogsmembers


  • [ Home ] [ About ] [ Contact / Request ] [ Privacy Policy ]

    Copyright © 2001-2018 VetContact GmbH
    All rights reserved